Chronic Obstructive Pulmonary Disease Pipeline Analysis, 2022 | Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment Algorithm | Key Companies - EpiEndo (EP395), Verona, Therapeutic Sol

As per DelveInsight's assessment, globally, about 70+ key pharma and biotech companies are working on 70+ pipeline drugs in the Chronic Obstructive Pulmonary Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. The Chronic Obstructive Pulmonary Disease (COPD) pipeline possesses potential drugs in mid-stage developments to be launched in the near future.

As per DelveInsight, the Chronic Obstructive Pulmonary Disease therapeutics market is anticipated to grow in the coming years owing to the increasing prevalent population of Chronic Obstructive Pulmonary Disease (COPD) patients, increased awareness of the unique histology of the disease that has allowed for the development of drugs that are specific to COPD, and the launch of emerging therapies.

"Chronic Obstructive Pulmonary Disease Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chronic Obstructive Pulmonary Disease Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Chronic Obstructive Pulmonary Disease Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Chronic Obstructive Pulmonary Disease Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Obstructive Pulmonary Disease treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Obstructive Pulmonary Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Obstructive Pulmonary Disease Therapeutics Analysis
There are approx. 70+ key companies developing therapies for Chronic Obstructive Pulmonary Disease. Currently, AstraZeneca is leading the therapeutics market with its Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Chronic Obstructive Pulmonary Disease Therapeutics Market Include:
GlaxoSmithKline, Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, AstraZeneca, Immunotek, Astrazeneca, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., CSL Behring; Grifols Biologicals, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, Glenmark Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Idorsia Pharmaceuticals, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, Boehringer Ingelheim, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Rhizen Pharmaceuticals, Foresee Pharmaceuticals, Brickell Biotech, and others.

Chronic Obstructive Pulmonary Disease Emerging Drugs
- Benralizumab: AstraZeneca
- MV130: Inmunotek S.L.
- SB-240563: GlaxoSmithKline
- CHF 6001: Chiesi Farmaceutici S.p.A.
- YPL 001: Yungjin Pharm. Co., Ltd.
- Tyvaso (Inhaled treprostinil solution): United Therapeutics
- Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb): Sanofi/Regeneron
And Many More

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Chronic Obstructive Pulmonary Disease Current Treatment Patterns
4. Chronic Obstructive Pulmonary Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chronic Obstructive Pulmonary Disease Late Stage Products (Phase-III)
7. Chronic Obstructive Pulmonary Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Obstructive Pulmonary Disease Discontinued Products
13. Chronic Obstructive Pulmonary Disease Product Profiles
14. Chronic Obstructive Pulmonary Disease Key Companies
15. Chronic Obstructive Pulmonary Disease Key Products
16. Dormant and Discontinued Products
17. Chronic Obstructive Pulmonary Disease Unmet Needs
18. Chronic Obstructive Pulmonary Disease Future Perspectives
19. Chronic Obstructive Pulmonary Disease Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.